Abstract
The debate over prostate cancer screening has raged for decades. Two large randomised studies tested whether screening reduces prostate cancer mortality and, while the US trial reported no benefit,1 the European (ERSPC) trial noted a significant reduction in mortality.2 In The Lancet, Fritz Schroder and colleagues3 now report 13-year mortality data from the ERSPC study. At 9 years, screening appeared to reduce prostate cancer mortality by 15% (rate ratio 0·85, 95% CI 0·70–1·03); this reduction was 22% at 11 years (0·78, 0·66–0·91) and 21% at 13 years (0·79, 0·69–0·91).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
